biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Purchases 13,532 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc bought 13,532 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average cost of $3.21 per share, for a total transaction of $43,437.72. Following the completion of the purchase, the insider now owns 4,156,426 shares of the company’s stock, valued at $13,342,127.46. This represents a 0.33 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Guines Llc also recently made the following trade(s):

• On Monday, April 7th, Guines Llc acquired 43,378 shares of biote stock. The shares were bought at an average cost of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc bought 7,321 shares of biote stock. The stock was purchased at an average cost of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc purchased 106,000 shares of biote stock. The stock was purchased at an average price of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The shares were purchased at an average price of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was acquired at an average cost of $3.22 per share, with a total value of $2,415,000.00.

biote Stock Performance

Shares of BTMD opened at $3.65 on Friday. The firm has a market capitalization of $199.69 million, a P/E ratio of 14.04 and a beta of 1.17. biote Corp. has a 52 week low of $3.04 and a 52 week high of $8.44. The stock has a 50 day moving average price of $4.06 and a two-hundred day moving average price of $5.19.

Analyst Ratings Changes

Separately, Craig Hallum dropped their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Institutional Investors Weigh In On biote

Institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its holdings in shares of biote by 52.3% in the third quarter. Barclays PLC now owns 77,196 shares of the company’s stock valued at $432,000 after purchasing an additional 26,510 shares during the last quarter. Kanen Wealth Management LLC bought a new stake in biote in the 4th quarter worth about $1,791,000. State Street Corp lifted its position in shares of biote by 13.7% during the 3rd quarter. State Street Corp now owns 475,491 shares of the company’s stock worth $2,653,000 after buying an additional 57,290 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after buying an additional 3,342 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in shares of biote by 56.4% in the fourth quarter. Sei Investments Co. now owns 18,321 shares of the company’s stock valued at $113,000 after acquiring an additional 6,605 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.